bioRxivCancer BiologyPreprint
Orthotopic injection of an established syngeneic mouse oral cancer cell line (MOC1) induces a robust draining lymph node response
Abstract
BackgroundPreclinical models are invaluable for studies on the pathogenesis and treatment of head and neck cancer. In recent years, there has been growing interest in the use of orthotopic syngeneic models, wherein head and neck cancer cell lines are injected into the oral cavity of immunocompetent mice. However, few such orthotopic models have been described in detail. In this brief report, we describe techniques for injection of mouse oral cancer 1 (MOC1) cells into the buccal mucosa and illustrate the tumor growth pattern, lymph node response, and changes in the tumor immune microenvironment over time. MethodsMOC1 cells were injected into the buccal mucosa of C57BL6 mice. Animals were sacrificed at 7, 14, 21, or 27 days. Tumors and lymph nodes were harvested and analyzed for immune cell subsets by flow cytometry. ResultsAll inoculated mice developed palpable buccal tumors by day 7 and required euthanasia for tumor burden and/or weight loss by day 27. Lymph node mapping showed that these tumors reliably drain to a submandibular lymph node, which enlarges considerably over time. As in MOC1 tumors in the flank, the proportion of intratumoral CD8+ T cells decreased over time, while neutrophilic myeloid cells increased dramatically. However, the pattern and time course of immune changes in the TME were slightly different in the orthotopic buccal model. ConclusionsWhen used orthotopically in the buccal mucosa, the MOC1 model induces a robust lymph node response and distinct pattern of immune cell infiltration, with peak immune infiltration by day 14.
- organism: mouse
- assay: flow cytometry
- research focus: cell type annotation
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A Novel Syngeneic Mouse Model to Study Immune Evasion in Head and Neck Squamous Cell Carcinoma
Mari Iida, Bridget E. Crossman, … Deric L. Wheeler·bioRxiv·Jul 23, 2026
- Novel syngeneic animal model of tobacco-associated oral cancer reveals the activity of in situ anti-CTLA-4
Z. Wang, V. H. Wu, … J. S. Gutkind·bioRxiv·Jun 15, 2019
- A Humanized Mouse Model of Oral Squamous Cell Carcinoma for Investigating Resistance to Anti-PD1 Immunotherapy
Amit Kumar Chakraborty, Chumki Choudhury, … Manish V. Bais·bioRxiv·Jun 13, 2025
- A new immunocompetent rectal cancer model to study radiation therapy
J. K. Kim, C. Wu, … J. J. Smith·bioRxiv·Feb 7, 2022
- Microneedle-mediated intratumoral delivery of anti-CTLA-4 promotes cDC1-dependent eradication of oral squamous cell carcinoma with limited irAEs
M. Gilardi, R. Saddawi-Konefka, … J. S. Gutkind·bioRxiv·Dec 7, 2021
- An immunocompetent Merkel cell carcinoma model for preclinical studies
Monique Elise Verhaegen, Simar Bhatia, … Andrzej Antoni Dlugosz·bioRxiv·Jun 26, 2026